{"filing":{"accession_number":"0001728117-26-000104","cik":"0001728117","ticker":"GOSS","company_name":"Gossamer Bio, Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"goss-20260923.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000104/goss-20260923.htm"},"events":[{"id":34576,"run_id":31821,"accession_number":"0001728117-26-000104","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Gossamer Bio announced submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH treatment in September 2026, supported by Phase 3 PROSERA and Phase 2 TORREY studies. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company whose future depends entirely on seralutinib's success, as disclosed in the forward-looking statements. While not a specific named event type, this represents a significant operational/regulatory development that would affect a reasonable investor's assessment of the company's progress toward commercialization.","company_name":"Gossamer Bio, Inc.","ticker":"GOSS","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38334,"accession_number":"0001728117-26-000104","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Gossamer Bio announced submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH treatment in September 2026, supported by Phase 3 PROSERA and Phase 2 TORREY studies. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company whose future depends entirely on seralutinib's success, as disclosed in the forward-looking statements. While not a specific named event type, this represents a significant operational/regulatory development that would affect a reasonable investor's assessment of the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:09:26.340708+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38334,"accession_number":"0001728117-26-000104","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Gossamer Bio announced submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH treatment in September 2026, supported by Phase 3 PROSERA and Phase 2 TORREY studies. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company whose future depends entirely on seralutinib's success, as disclosed in the forward-looking statements. While not a specific named event type, this represents a significant operational/regulatory development that would affect a reasonable investor's assessment of the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:09:26.340708+00:00","company_name":"Gossamer Bio, Inc.","ticker":"GOSS","filing_date":"2026-09-23"}]}